Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology

Executive Summary

Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.

You may also be interested in...



Oncology Deal-Making The Daiichi Way

Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.

Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project

Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib

Oncology news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel